PHAT — Phathom Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $919.43m
- $1.34bn
- $55.25m
Annual income statement for Phathom Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0.682 | 55.3 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | 0.515 | 47.3 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 126 | 137 | 172 | 168 | 333 |
| Operating Profit | -126 | -137 | -172 | -167 | -277 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -129 | -144 | -198 | -202 | -334 |
| Net Income After Taxes | -129 | -144 | -198 | -202 | -334 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -129 | -144 | -198 | -202 | -334 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -129 | -144 | -198 | -202 | -334 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.88 | -4.65 | -5.05 | -3.93 | -5.29 |